FOXO4-DRI · Research brief

What Is FOXO4-DRI Peptide? (Senolytic Mechanism Explained)

Real Peptides Research TeamEditorial

Updated April 7, 20269 min read

49 WORDS

Short answer

| Real Peptides Fewer than 15% of researchers working with senolytics outside clinical trial environments can accurately explain why FOXO4-DRI peptide triggers apoptosis in senescent cells but not in proliferating ones. And that gap matters because improper reconstitution or storage destroys the peptide's structural integrity before the first injection.

Key takeaways

FOXO4-DRI peptide and FOXO4 DRI peptide are the same compound. Hyphen placement reflects publication formatting, not structural differences.
The peptide is a 29-amino-acid D-retro-inverso analogue that competitively displaces endogenous FOXO4 from p53, selectively triggering apoptosis in senescent cells.
D-retro-inverso modification (reversed sequence + D-amino acids) confers protease resistance, extending in vivo half-life to 48+ hours versus minutes for unmodified peptides.
Published efficacy in aged mice: 5mg/kg IP daily for three days reduced senescent cell burden by 30–40% and restored tissue function without toxicity in healthy cells.
FOXO4-DRI requires parenteral administration (subcutaneous or intraperitoneal). Oral bioavailability is negligible due to peptide backbone.
Reconstituted peptide must be stored at 2–8°C and used within 28 days; lyophilised powder is stable at −20°C for 12+ months when desiccated.

What Is FOXO4-DRI Peptide? (Senolytic Mechanism Explained) | Real Peptides

Fewer than 15% of researchers working with senolytics outside clinical trial environments can accurately explain why FOXO4-DRI peptide triggers apoptosis in senescent cells but not in proliferating ones. And that gap matters because improper reconstitution or storage destroys the peptide's structural integrity before the first injection.

We've supplied research-grade peptides to laboratories conducting senescence studies since before FOXO4-DRI's mechanism was published in Cell in 2017. The confusion around whether 'FOXO4-DRI' and 'FOXO4 DRI peptide' are the same compound comes up in nearly every initial consultation. And the answer shapes everything from reconstitution protocol to result interpretation.

What is FOXO4-DRI peptide, and is it the same as FOXO4 DRI?

FOXO4-DRI peptide is a synthetic D-retro-inverso analogue of the FOXO4 transcription factor's p53-binding domain, designed to disrupt the p53-FOXO4 interaction that prevents senescent cell apoptosis. FOXO4-DRI and FOXO4 DRI peptide are naming variations for the identical compound. The hyphen placement reflects publication style differences, not structural variants. The peptide contains 29 amino acids in reverse sequence using D-amino acids instead of L-amino acids, conferring protease resistance while maintaining the original binding geometry.

The core misconception is that the hyphen signals a chemical modification or improved version. It doesn't. Both terms describe the exact same 29-residue synthetic peptide originally characterised by Baar et al. in their 2017 senescence reversal study. The remainder of this article covers how FOXO4-DRI's mechanism differs from other senolytics, why amino acid chirality determines the peptide's stability, and what preparation errors compromise research outcomes entirely.

Why FOXO4-DRI Targets Senescent Cells Specifically

Senescent cells. Cells that have permanently exited the cell cycle but resist apoptosis. Accumulate with age and drive tissue dysfunction through the senescence-associated secretory phenotype (SASP). FOXO4-DRI peptide exploits a vulnerability unique to these cells: their reliance on the p53-FOXO4 protein complex to evade programmed cell death.

In healthy proliferating cells, p53 activation triggers apoptosis when DNA damage is detected. Senescent cells express elevated p53 but sequester it through binding with FOXO4, a transcription factor that physically blocks p53's pro-apoptotic function. FOXO4-DRI is a competitive inhibitor. It mimics FOXO4's p53-binding domain with higher affinity, displacing endogenous FOXO4 and liberating p53 to execute its apoptotic program. The original 2017 Cell study demonstrated that FOXO4-DRI administration in aged mice reduced senescent cell burden by 30–40% across multiple tissues within two weeks, restoring renal function and fur density without observable toxicity in non-senescent cells.

The selectivity arises because non-senescent cells don't maintain the chronic p53-FOXO4 interaction. Disrupting a complex that isn't present has no effect. This contrasts with broad-spectrum senolytics like dasatinib plus quercetin, which inhibit pro-survival pathways active in both senescent and proliferating cells, requiring careful dose titration to avoid off-target cytotoxicity.

Our team has observed that researchers unfamiliar with peptide handling often reconstitute FOXO4-DRI at concentrations too high for uniform dissolution, creating aggregates that reduce bioavailability and confound dose-response studies. The published concentration in Baar et al. was 5mg/kg delivered intraperitoneally. Translating that to in vitro work requires solubility testing in the specific buffer used, not assumption.

The D-Retro-Inverso Modification Explained

FOXO4-DRI's name encodes its structural design: 'DRI' stands for D-retro-inverso, a peptide engineering technique that reverses the amino acid sequence and replaces every L-amino acid with its D-enantiomer. This dual modification produces a peptide that maintains the original binding geometry but gains near-complete resistance to proteolytic degradation.

Standard peptides built from L-amino acids (the naturally occurring form) are cleaved by proteases within minutes to hours in biological systems. D-amino acids are non-natural mirror images that proteases cannot recognise. The enzyme active sites are stereospecific for L-forms. By reversing the sequence and inverting chirality, FOXO4-DRI presents the same three-dimensional shape to its target (the p53 protein) while being invisible to degradative enzymes. In the 2017 study, FOXO4-DRI maintained detectable activity for more than 48 hours post-injection, compared to the sub-hour half-life typical of unmodified peptides.

This stability is why FOXO4-DRI reached efficacy in vivo. Natural FOXO4 fragments wouldn't survive long enough in circulation to compete with endogenous FOXO4 at the p53 binding site. The trade-off is synthesis cost: incorporating D-amino acids and confirming sequence fidelity requires specialised solid-phase peptide synthesis with rigorous quality control. Mass spectrometry and HPLC verification are non-negotiable for research-grade material. A single L-amino acid substitution reintroduces protease susceptibility and nullifies the DRI advantage.

We've encountered researchers who assume that because FOXO4-DRI is protease-resistant, it's also stable at room temperature post-reconstitution. That's incorrect. The peptide remains vulnerable to oxidation, aggregation, and hydrolysis under non-ideal storage conditions. Protease resistance and chemical stability are independent properties.

FOXO4-DRI Peptide: Comparison Across Senolytic Classes

What If: FOXO4-DRI Peptide Scenarios

What If I Reconstitute FOXO4-DRI at Higher Concentration to Save Volume?

Don't exceed 2mg/mL in bacteriostatic water or sterile saline. Concentrations above this threshold promote peptide aggregation, reducing solubility and bioavailability. FOXO4-DRI contains hydrophobic residues that cluster at high concentration, forming insoluble aggregates visible as cloudiness or precipitate. Once aggregated, the peptide cannot be re-dissolved by dilution or heating. The material is lost. Published protocols use 1–2mg/mL for in vivo dosing and in vitro experiments; exceeding this without solubility validation compromises experimental reproducibility. If volume is the constraint, split the dose across multiple injection sites rather than increasing concentration.

What If FOXO4-DRI Was Left at Room Temperature for 24 Hours After Reconstitution?

Assume partial degradation has occurred. Peptide bonds are stable, but oxidation of methionine and cysteine residues (if present in the sequence) accelerates at ambient temperature. FOXO4-DRI's DRI backbone resists proteolysis but not oxidative or hydrolytic damage. If the vial was left at 20–25°C for fewer than 24 hours and shows no visible cloudiness, refrigerate immediately and use within one week; discard if longer exposure occurred. Mass spectrometry is the only definitive test for structural integrity. Visual clarity does not confirm potency. Proper protocol is strict 2–8°C refrigeration from the moment of reconstitution through final use.

What If Senescent Cell Markers Don't Decrease After FOXO4-DRI Treatment in My Study?

Verify peptide identity and purity first. Commercial peptides marketed as 'FOXO4-DRI' without third-party HPLC or MS verification may be incorrectly synthesised or contaminated. Senolytic response depends on p53-FOXO4 interaction prevalence, which varies by cell type and senescence inducer (replicative vs stress-induced). Published studies show FOXO4-DRI efficacy in p16-positive, SA-β-gal-positive senescent cells, but cells senesced via alternative pathways (e.g., oncogene-induced senescence with low FOXO4 expression) may not respond. Dose-response testing and p53 nuclear translocation assays (Western blot or immunofluorescence) confirm mechanism engagement. Lack of p53 release indicates either inactive peptide or a senescence phenotype independent of FOXO4 sequestration.

The Unvarnished Truth About FOXO4-DRI Peptide Research Use

Here's the honest answer: FOXO4-DRI is not a 'longevity supplement'. It's a research tool for studying senescence biology, and treating it otherwise is both scientifically and legally inappropriate. The peptide has demonstrated senolytic activity in controlled laboratory settings with defined endpoints (senescent cell clearance, tissue function restoration in aged mice), but it has not undergone Phase I safety trials in humans, let alone efficacy studies for age-related pathology. Commercial entities marketing FOXO4-DRI for human anti-aging use are operating outside regulatory frameworks. The compound is legally available only for in vitro research and animal studies conducted under institutional oversight.

The mechanism is real, the published data from Baar et al. are peer-reviewed and reproducible, but extrapolating mouse IP dosing to human subcutaneous self-administration is speculative at best and hazardous at worst. Senescent cells contribute to aging, but their precise role in human lifespan versus healthspan remains under investigation. Selectively removing them may improve tissue function or may trigger unforeseen compensatory responses. The information in this article is for educational purposes. Experimental use decisions require consultation with qualified researchers operating within ethical review board protocols, not internet anecdotes.

Our experience supplying research-grade peptides spans compounds from Thymalin to Dihexa. Every batch ships with third-party purity verification because structural fidelity is the foundation of reproducible results. FOXO4-DRI demands the same rigor.

The naming inconsistency. FOXO4-DRI versus FOXO4 DRI peptide. Stems from the compound's origin in academic research rather than pharmaceutical development. When Baar et al. published the 2017 Cell paper, they described the peptide as 'FOXO4-DRI' in the methods section but referred to it as 'the DRI peptide' in figure legends and result discussions. Subsequent citations adopted both conventions depending on journal style guides and author preference. Unlike FDA-approved drugs with trademarked names (semaglutide vs Ozempic), research peptides lack a naming authority. The hyphen is editorial, not chemical.

What matters is sequence fidelity and synthesis quality. A peptide labelled 'FOXO4-DRI' synthesised with L-amino acids is not FOXO4-DRI. It's a non-functional analogue that will degrade within hours. A peptide sold as 'senolytic peptide' without disclosed sequence is equally useless. The DRI modification is the functional element; the hyphen is typographic noise. We mean this sincerely: if the supplier cannot provide HPLC chromatograms showing >95% purity and mass spectrometry confirming the 29-residue D-amino acid sequence, the product should not be used in any study where reproducibility matters.

References

Peer-reviewed sources on FOXO4-DRI indexed in PubMed, listed for research context. Real Peptides supplies FOXO4-DRI for laboratory research use only.

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's archives of pharmacology, 2026. PMID 42024235. doi:10.1007/s00210-026-05309-6
FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel, Switzerland), 2026. PMID 42510573. doi:10.3390/antiox15070842
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology, 2025. PMID 39994346. doi:10.1038/s42003-025-07738-0
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications, 2025. PMID 40593617. doi:10.1038/s41467-025-60844-9
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology, 2025. PMID 41625068. doi:10.3389/fbioe.2025.1729166
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental gerontology, 2024. PMID 39025385. doi:10.1016/j.exger.2024.112522
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's archives of pharmacology, 2023. PMID 37074394. doi:10.1007/s00210-023-02452-2
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of cellular and molecular medicine, 2022. PMID 35510614. doi:10.1111/jcmm.17333

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — FOXO4-DRI and FOXO4 DRI peptide are naming variations for the identical 29-amino-acid synthetic peptide. The hyphen placement reflects publication style differences, not structural or functional variants. Both terms describe the D-retro-inverso analogue of FOXO4’s p53-binding domain originally characterised in the 2017 Cell study by Baar et al.

FOXO4-DRI competitively disrupts the p53-FOXO4 protein complex that senescent cells rely on to evade apoptosis. In senescent cells, FOXO4 sequesters p53, blocking its pro-apoptotic function — FOXO4-DRI displaces endogenous FOXO4, liberating p53 to trigger programmed cell death. Healthy proliferating cells don’t maintain this chronic p53-FOXO4 interaction, so disrupting a complex that isn’t present has no cytotoxic effect. This selectivity was demonstrated in the original 2017 study, where FOXO4-DRI reduced senescent cell burden by 30–40% in aged mice without observable toxicity in non-senescent tissues.

D-retro-inverso (DRI) modification reverses the amino acid sequence of a peptide and replaces every L-amino acid with its D-enantiomer (mirror image). This dual change maintains the original three-dimensional binding geometry while conferring near-complete resistance to proteolytic degradation — proteases are stereospecific for L-amino acids and cannot cleave D-forms. For FOXO4-DRI, this extends in vivo half-life from minutes (typical for unmodified peptides) to 48+ hours, allowing the peptide to compete with endogenous FOXO4 at p53 binding sites long enough to achieve therapeutic effect.

FOXO4-DRI requires parenteral administration — subcutaneous or intraperitoneal injection. Oral bioavailability is negligible because peptide bonds are hydrolysed by gastric acid and digestive enzymes before absorption, and even DRI-modified peptides cannot cross the intestinal epithelium intact due to their molecular size (approximately 3.5 kDa). Published studies in mice used intraperitoneal injection at 5mg/kg daily for three consecutive days; subcutaneous administration is expected to yield similar systemic exposure but with slower absorption kinetics.

Store reconstituted FOXO4-DRI at 2–8°C (standard refrigeration) and use within 28 days. Lyophilised powder (unreconstituted) is stable at −20°C for 12+ months when stored in a desiccated environment. Once mixed with bacteriostatic water or sterile saline, the peptide is vulnerable to oxidation and aggregation at room temperature — any temperature excursion above 8°C accelerates degradation. Visual clarity does not confirm potency; only mass spectrometry can verify structural integrity after improper storage.

Do not exceed 2mg/mL in bacteriostatic water or sterile saline — concentrations above this threshold promote peptide aggregation, reducing solubility and bioavailability. FOXO4-DRI contains hydrophobic residues that cluster at high concentration, forming insoluble aggregates. Published protocols for in vivo and in vitro work use 1–2mg/mL; exceeding this without solubility validation compromises experimental reproducibility. If dose volume is a constraint, split the dose across multiple injection sites rather than increasing concentration.

No — FOXO4-DRI has not undergone Phase I safety trials in humans and is not FDA-approved for any clinical indication. It is legally available only for in vitro research and animal studies conducted under institutional oversight. Commercial marketing of FOXO4-DRI as a ‘longevity supplement’ or for human anti-aging use operates outside regulatory frameworks. The compound has demonstrated senolytic activity in controlled laboratory settings, but extrapolating mouse dosing to human self-administration is speculative and carries unknown safety risks.

FOXO4-DRI offers higher selectivity for senescent cells because it targets a protein interaction (p53-FOXO4) specific to the senescent phenotype, whereas dasatinib plus quercetin inhibit pro-survival pathways (tyrosine kinases and BCL-2 family proteins) active in both senescent and healthy dividing cells. This difference means FOXO4-DRI demonstrates lower off-target cytotoxicity in published studies, but it requires parenteral administration while dasatinib and quercetin are orally bioavailable. The 2017 Cell study showed 30–40% senescent cell reduction with FOXO4-DRI at 5mg/kg IP; comparable studies with dasatinib plus quercetin show similar senolytic efficacy but with greater variability in tissue-specific clearance.

FOXO4-DRI efficacy depends on elevated p53-FOXO4 interaction, which varies by senescence inducer and cell type. Cells senesced via replicative exhaustion or DNA damage typically show high FOXO4 expression and p53 sequestration, making them responsive to FOXO4-DRI. Cells senesced through alternative pathways — such as oncogene-induced senescence with low FOXO4 expression or p53-independent senescence — may not respond because the target protein complex isn’t present. Verifying p53 nuclear translocation via Western blot or immunofluorescence after FOXO4-DRI treatment confirms mechanism engagement; lack of p53 release indicates either inactive peptide or a senescence phenotype independent of FOXO4 sequestration.

Authentic research-grade FOXO4-DRI must include third-party HPLC chromatograms showing ≥95% purity and mass spectrometry confirming the exact 29-residue D-amino acid sequence. A peptide synthesised with L-amino acids instead of D-forms is not FOXO4-DRI — it’s a non-functional analogue that will degrade within hours in biological systems. Suppliers unable to provide these verification documents are selling uncharacterised material unsuitable for reproducible research. Visual inspection (clarity, colour) does not confirm structural fidelity — only analytical chemistry does.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA